nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—atopic dermatitis	0.374	1	CbGaD
Thalidomide—PTGS1—Diphenhydramine—atopic dermatitis	0.0428	0.13	CbGbCtD
Thalidomide—PTGS2—Triamcinolone—atopic dermatitis	0.0352	0.107	CbGbCtD
Thalidomide—CYP3A5—Tacrolimus—atopic dermatitis	0.0351	0.106	CbGbCtD
Thalidomide—PTGS2—Betamethasone—atopic dermatitis	0.0302	0.0914	CbGbCtD
Thalidomide—CYP2C19—Loratadine—atopic dermatitis	0.0207	0.0628	CbGbCtD
Thalidomide—CYP2C19—Diphenhydramine—atopic dermatitis	0.0207	0.0628	CbGbCtD
Thalidomide—CYP1A2—Diphenhydramine—atopic dermatitis	0.0191	0.058	CbGbCtD
Thalidomide—PTGS2—Dexamethasone—atopic dermatitis	0.0175	0.0532	CbGbCtD
Thalidomide—CYP2C9—Loratadine—atopic dermatitis	0.0172	0.0522	CbGbCtD
Thalidomide—CYP2C9—Diphenhydramine—atopic dermatitis	0.0172	0.0522	CbGbCtD
Thalidomide—CYP1A1—Dexamethasone—atopic dermatitis	0.0148	0.0449	CbGbCtD
Thalidomide—CYP3A5—Hydrocortisone—atopic dermatitis	0.0143	0.0433	CbGbCtD
Thalidomide—CYP2C19—Prednisone—atopic dermatitis	0.0115	0.0348	CbGbCtD
Thalidomide—CYP2E1—Dexamethasone—atopic dermatitis	0.0114	0.0347	CbGbCtD
Thalidomide—CYP3A5—Dexamethasone—atopic dermatitis	0.00889	0.027	CbGbCtD
Thalidomide—CYP2C19—Dexamethasone—atopic dermatitis	0.00717	0.0217	CbGbCtD
Thalidomide—CYP2C9—Dexamethasone—atopic dermatitis	0.00596	0.0181	CbGbCtD
Thalidomide—Pomalidomide—TNF—atopic dermatitis	0.00231	1	CrCbGaD
Thalidomide—FGFR2—skin epidermis—atopic dermatitis	0.00229	0.269	CbGeAlD
Thalidomide—FGFR2—neck—atopic dermatitis	0.00109	0.129	CbGeAlD
Thalidomide—CYP1A1—skin epidermis—atopic dermatitis	0.000827	0.0973	CbGeAlD
Thalidomide—FGFR2—skin of body—atopic dermatitis	0.000708	0.0833	CbGeAlD
Thalidomide—PTGS2—skin epidermis—atopic dermatitis	0.000695	0.0817	CbGeAlD
Thalidomide—NFKB1—head—atopic dermatitis	0.000615	0.0723	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Desonide—atopic dermatitis	0.000536	0.165	CbGdCrCtD
Thalidomide—CRBN—head—atopic dermatitis	0.000516	0.0606	CbGeAlD
Thalidomide—FGFR2—head—atopic dermatitis	0.000462	0.0543	CbGeAlD
Thalidomide—PTGS2—Fluocinonide—Fluocinolone Acetonide—atopic dermatitis	0.000418	0.128	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Mometasone—atopic dermatitis	0.000333	0.102	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Fluocinonide—atopic dermatitis	0.000259	0.0797	CbGdCrCtD
Thalidomide—CYP1A1—skin of body—atopic dermatitis	0.000256	0.0301	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—atopic dermatitis	0.000252	0.0774	CbGdCrCtD
Thalidomide—PTGS1—skin of body—atopic dermatitis	0.000225	0.0265	CbGeAlD
Thalidomide—PTGS2—skin of body—atopic dermatitis	0.000215	0.0253	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Mometasone—atopic dermatitis	0.000201	0.0618	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Methylprednisolone—atopic dermatitis	0.000199	0.0612	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Betamethasone—atopic dermatitis	0.000196	0.0602	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Dexamethasone—atopic dermatitis	0.000196	0.0602	CbGdCrCtD
Thalidomide—PTGS2—Fluocinonide—Triamcinolone—atopic dermatitis	0.000191	0.0588	CbGdCrCtD
Thalidomide—CYP1A1—head—atopic dermatitis	0.000167	0.0197	CbGeAlD
Thalidomide—CYP2E1—head—atopic dermatitis	0.000153	0.0179	CbGeAlD
Thalidomide—PTGS1—head—atopic dermatitis	0.000147	0.0173	CbGeAlD
Thalidomide—PTGS2—head—atopic dermatitis	0.00014	0.0165	CbGeAlD
Thalidomide—PTGS2—Fluticasone Propionate—Methylprednisolone—atopic dermatitis	0.00012	0.0369	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Betamethasone—atopic dermatitis	0.000118	0.0363	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Dexamethasone—atopic dermatitis	0.000118	0.0363	CbGdCrCtD
Thalidomide—PTGS2—Fluticasone Propionate—Triamcinolone—atopic dermatitis	0.000115	0.0355	CbGdCrCtD
Thalidomide—Dermatitis—Tacrolimus—atopic dermatitis	5.12e-05	0.000304	CcSEcCtD
Thalidomide—Shock—Prednisolone—atopic dermatitis	5.1e-05	0.000304	CcSEcCtD
Thalidomide—Cough—Triamcinolone—atopic dermatitis	5.1e-05	0.000304	CcSEcCtD
Thalidomide—Headache—Tacrolimus—atopic dermatitis	5.09e-05	0.000303	CcSEcCtD
Thalidomide—Oedema—Hydrocortisone—atopic dermatitis	5.07e-05	0.000302	CcSEcCtD
Thalidomide—Convulsion—Triamcinolone—atopic dermatitis	5.06e-05	0.000301	CcSEcCtD
Thalidomide—Tachycardia—Prednisolone—atopic dermatitis	5.06e-05	0.000301	CcSEcCtD
Thalidomide—Convulsion—Methylprednisolone—atopic dermatitis	5.05e-05	0.000301	CcSEcCtD
Thalidomide—Hypertension—Triamcinolone—atopic dermatitis	5.05e-05	0.0003	CcSEcCtD
Thalidomide—Hypertension—Methylprednisolone—atopic dermatitis	5.04e-05	0.0003	CcSEcCtD
Thalidomide—Infection—Hydrocortisone—atopic dermatitis	5.03e-05	0.0003	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisolone—atopic dermatitis	5.01e-05	0.000298	CcSEcCtD
Thalidomide—Shock—Hydrocortisone—atopic dermatitis	4.98e-05	0.000297	CcSEcCtD
Thalidomide—Myalgia—Triamcinolone—atopic dermatitis	4.98e-05	0.000296	CcSEcCtD
Thalidomide—Nervous system disorder—Hydrocortisone—atopic dermatitis	4.97e-05	0.000296	CcSEcCtD
Thalidomide—Arthralgia—Methylprednisolone—atopic dermatitis	4.97e-05	0.000296	CcSEcCtD
Thalidomide—Myalgia—Methylprednisolone—atopic dermatitis	4.97e-05	0.000296	CcSEcCtD
Thalidomide—Eye disorder—Prednisone—atopic dermatitis	4.96e-05	0.000295	CcSEcCtD
Thalidomide—Anxiety—Methylprednisolone—atopic dermatitis	4.95e-05	0.000294	CcSEcCtD
Thalidomide—Tachycardia—Hydrocortisone—atopic dermatitis	4.94e-05	0.000294	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—atopic dermatitis	4.93e-05	0.000293	CcSEcCtD
Thalidomide—Skin disorder—Hydrocortisone—atopic dermatitis	4.92e-05	0.000293	CcSEcCtD
Thalidomide—Ill-defined disorder—Dexamethasone—atopic dermatitis	4.92e-05	0.000293	CcSEcCtD
Thalidomide—Ill-defined disorder—Betamethasone—atopic dermatitis	4.92e-05	0.000293	CcSEcCtD
Thalidomide—Discomfort—Triamcinolone—atopic dermatitis	4.92e-05	0.000293	CcSEcCtD
Thalidomide—Discomfort—Methylprednisolone—atopic dermatitis	4.91e-05	0.000292	CcSEcCtD
Thalidomide—Hyperhidrosis—Hydrocortisone—atopic dermatitis	4.9e-05	0.000291	CcSEcCtD
Thalidomide—FGFR2—IRS-mediated signalling—IL6—atopic dermatitis	4.88e-05	0.000429	CbGpPWpGaD
Thalidomide—Dry mouth—Triamcinolone—atopic dermatitis	4.87e-05	0.00029	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—NFKBIA—atopic dermatitis	4.86e-05	0.000427	CbGpPWpGaD
Thalidomide—Angioedema—Betamethasone—atopic dermatitis	4.85e-05	0.000288	CcSEcCtD
Thalidomide—Angioedema—Dexamethasone—atopic dermatitis	4.85e-05	0.000288	CcSEcCtD
Thalidomide—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARA—atopic dermatitis	4.84e-05	0.000425	CbGpPWpGaD
Thalidomide—Anorexia—Hydrocortisone—atopic dermatitis	4.83e-05	0.000287	CcSEcCtD
Thalidomide—NFKB1—Toll Like Receptor 9 (TLR9) Cascade—IL6—atopic dermatitis	4.83e-05	0.000424	CbGpPWpGaD
Thalidomide—NFKB1—TNF alpha Signaling Pathway—IL6—atopic dermatitis	4.83e-05	0.000424	CbGpPWpGaD
Thalidomide—Nausea—Tacrolimus—atopic dermatitis	4.82e-05	0.000287	CcSEcCtD
Thalidomide—Angiopathy—Prednisone—atopic dermatitis	4.81e-05	0.000287	CcSEcCtD
Thalidomide—Confusional state—Methylprednisolone—atopic dermatitis	4.8e-05	0.000286	CcSEcCtD
Thalidomide—TNF—Folate Metabolism—IL6—atopic dermatitis	4.8e-05	0.000422	CbGpPWpGaD
Thalidomide—Immune system disorder—Prednisone—atopic dermatitis	4.79e-05	0.000285	CcSEcCtD
Thalidomide—Malaise—Betamethasone—atopic dermatitis	4.78e-05	0.000285	CcSEcCtD
Thalidomide—Malaise—Dexamethasone—atopic dermatitis	4.78e-05	0.000285	CcSEcCtD
Thalidomide—Oedema—Triamcinolone—atopic dermatitis	4.77e-05	0.000284	CcSEcCtD
Thalidomide—Vertigo—Dexamethasone—atopic dermatitis	4.76e-05	0.000284	CcSEcCtD
Thalidomide—Vertigo—Betamethasone—atopic dermatitis	4.76e-05	0.000284	CcSEcCtD
Thalidomide—Syncope—Betamethasone—atopic dermatitis	4.76e-05	0.000283	CcSEcCtD
Thalidomide—Syncope—Dexamethasone—atopic dermatitis	4.76e-05	0.000283	CcSEcCtD
Thalidomide—FGFR2—IRS-related events—IL6—atopic dermatitis	4.75e-05	0.000417	CbGpPWpGaD
Thalidomide—NFKB1—MyD88:Mal cascade initiated on plasma membrane—IL6—atopic dermatitis	4.75e-05	0.000417	CbGpPWpGaD
Thalidomide—Arrhythmia—Prednisone—atopic dermatitis	4.74e-05	0.000282	CcSEcCtD
Thalidomide—Infection—Triamcinolone—atopic dermatitis	4.74e-05	0.000282	CcSEcCtD
Thalidomide—Hypotension—Hydrocortisone—atopic dermatitis	4.73e-05	0.000282	CcSEcCtD
Thalidomide—Infection—Methylprednisolone—atopic dermatitis	4.73e-05	0.000281	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—TLR2—atopic dermatitis	4.72e-05	0.000415	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KIF3A—atopic dermatitis	4.72e-05	0.000415	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—CXCL8—atopic dermatitis	4.71e-05	0.000414	CbGpPWpGaD
Thalidomide—FGFR2—IRS-related events triggered by IGF1R—IL6—atopic dermatitis	4.7e-05	0.000413	CbGpPWpGaD
Thalidomide—Shock—Triamcinolone—atopic dermatitis	4.69e-05	0.000279	CcSEcCtD
Thalidomide—Insomnia—Prednisolone—atopic dermatitis	4.69e-05	0.000279	CcSEcCtD
Thalidomide—Alopecia—Prednisone—atopic dermatitis	4.69e-05	0.000279	CcSEcCtD
Thalidomide—Shock—Methylprednisolone—atopic dermatitis	4.68e-05	0.000279	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—MAPK8—atopic dermatitis	4.67e-05	0.00041	CbGpPWpGaD
Thalidomide—Nervous system disorder—Methylprednisolone—atopic dermatitis	4.67e-05	0.000278	CcSEcCtD
Thalidomide—Loss of consciousness—Dexamethasone—atopic dermatitis	4.66e-05	0.000277	CcSEcCtD
Thalidomide—Loss of consciousness—Betamethasone—atopic dermatitis	4.66e-05	0.000277	CcSEcCtD
Thalidomide—Paraesthesia—Prednisolone—atopic dermatitis	4.66e-05	0.000277	CcSEcCtD
Thalidomide—Tachycardia—Triamcinolone—atopic dermatitis	4.66e-05	0.000277	CcSEcCtD
Thalidomide—Mental disorder—Prednisone—atopic dermatitis	4.65e-05	0.000277	CcSEcCtD
Thalidomide—Tachycardia—Methylprednisolone—atopic dermatitis	4.65e-05	0.000276	CcSEcCtD
Thalidomide—Skin disorder—Methylprednisolone—atopic dermatitis	4.62e-05	0.000275	CcSEcCtD
Thalidomide—Malnutrition—Prednisone—atopic dermatitis	4.62e-05	0.000275	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	4.62e-05	0.000406	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NFKBIA—atopic dermatitis	4.62e-05	0.000405	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Hydrocortisone—atopic dermatitis	4.62e-05	0.000275	CcSEcCtD
Thalidomide—Hyperhidrosis—Triamcinolone—atopic dermatitis	4.61e-05	0.000274	CcSEcCtD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	4.61e-05	0.000405	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FCER2—atopic dermatitis	4.61e-05	0.000405	CbGpPWpGaD
Thalidomide—Hyperhidrosis—Methylprednisolone—atopic dermatitis	4.6e-05	0.000274	CcSEcCtD
Thalidomide—Convulsion—Dexamethasone—atopic dermatitis	4.6e-05	0.000273	CcSEcCtD
Thalidomide—Convulsion—Betamethasone—atopic dermatitis	4.6e-05	0.000273	CcSEcCtD
Thalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—atopic dermatitis	4.59e-05	0.000403	CbGpPWpGaD
Thalidomide—Insomnia—Hydrocortisone—atopic dermatitis	4.58e-05	0.000273	CcSEcCtD
Thalidomide—FGFR2—Insulin receptor signalling cascade—IL6—atopic dermatitis	4.58e-05	0.000402	CbGpPWpGaD
Thalidomide—FGFR2—IGF1R signaling cascade—IL6—atopic dermatitis	4.58e-05	0.000402	CbGpPWpGaD
Thalidomide—Hypertension—Dexamethasone—atopic dermatitis	4.58e-05	0.000273	CcSEcCtD
Thalidomide—Hypertension—Betamethasone—atopic dermatitis	4.58e-05	0.000273	CcSEcCtD
Thalidomide—NFKB1—MyD88-independent cascade—IL6—atopic dermatitis	4.55e-05	0.0004	CbGpPWpGaD
Thalidomide—Paraesthesia—Hydrocortisone—atopic dermatitis	4.55e-05	0.000271	CcSEcCtD
Thalidomide—PTGS2—C-MYB transcription factor network—CD4—atopic dermatitis	4.52e-05	0.000397	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—atopic dermatitis	4.52e-05	0.000397	CbGpPWpGaD
Thalidomide—Myalgia—Dexamethasone—atopic dermatitis	4.52e-05	0.000269	CcSEcCtD
Thalidomide—Myalgia—Betamethasone—atopic dermatitis	4.52e-05	0.000269	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—IFNG—atopic dermatitis	4.51e-05	0.000396	CbGpPWpGaD
Thalidomide—Anxiety—Dexamethasone—atopic dermatitis	4.5e-05	0.000268	CcSEcCtD
Thalidomide—Anxiety—Betamethasone—atopic dermatitis	4.5e-05	0.000268	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—TLR2—atopic dermatitis	4.48e-05	0.000394	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	4.48e-05	0.000394	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KIF3A—atopic dermatitis	4.48e-05	0.000393	CbGpPWpGaD
Thalidomide—Discomfort—Dexamethasone—atopic dermatitis	4.46e-05	0.000266	CcSEcCtD
Thalidomide—Discomfort—Betamethasone—atopic dermatitis	4.46e-05	0.000266	CcSEcCtD
Thalidomide—Dyspepsia—Hydrocortisone—atopic dermatitis	4.46e-05	0.000265	CcSEcCtD
Thalidomide—Hypotension—Methylprednisolone—atopic dermatitis	4.45e-05	0.000265	CcSEcCtD
Thalidomide—NFKB1—Toll-like Receptor Signaling Pathway—IL6—atopic dermatitis	4.45e-05	0.000391	CbGpPWpGaD
Thalidomide—Pain—Prednisolone—atopic dermatitis	4.44e-05	0.000264	CcSEcCtD
Thalidomide—Decreased appetite—Hydrocortisone—atopic dermatitis	4.4e-05	0.000262	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Hydrocortisone—atopic dermatitis	4.37e-05	0.00026	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—FCER2—atopic dermatitis	4.37e-05	0.000384	CbGpPWpGaD
Thalidomide—Fatigue—Hydrocortisone—atopic dermatitis	4.37e-05	0.00026	CcSEcCtD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—atopic dermatitis	4.36e-05	0.000383	CbGpPWpGaD
Thalidomide—CYP1A1—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	4.36e-05	0.000383	CbGpPWpGaD
Thalidomide—Vision blurred—Prednisone—atopic dermatitis	4.35e-05	0.000259	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Triamcinolone—atopic dermatitis	4.35e-05	0.000259	CcSEcCtD
Thalidomide—NFKB1—Senescence-Associated Secretory Phenotype (SASP)—IL6—atopic dermatitis	4.34e-05	0.000382	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Methylprednisolone—atopic dermatitis	4.34e-05	0.000258	CcSEcCtD
Thalidomide—Pain—Hydrocortisone—atopic dermatitis	4.33e-05	0.000258	CcSEcCtD
Thalidomide—Oedema—Dexamethasone—atopic dermatitis	4.33e-05	0.000258	CcSEcCtD
Thalidomide—Oedema—Betamethasone—atopic dermatitis	4.33e-05	0.000258	CcSEcCtD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—atopic dermatitis	4.33e-05	0.00038	CbGpPWpGaD
Thalidomide—Insomnia—Triamcinolone—atopic dermatitis	4.31e-05	0.000257	CcSEcCtD
Thalidomide—NFKB1—Cellular Senescence—MAPK8—atopic dermatitis	4.31e-05	0.000378	CbGpPWpGaD
Thalidomide—Insomnia—Methylprednisolone—atopic dermatitis	4.3e-05	0.000256	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—TNF—atopic dermatitis	4.3e-05	0.000378	CbGpPWpGaD
Thalidomide—Infection—Betamethasone—atopic dermatitis	4.3e-05	0.000256	CcSEcCtD
Thalidomide—Infection—Dexamethasone—atopic dermatitis	4.3e-05	0.000256	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—CXCL8—atopic dermatitis	4.29e-05	0.000377	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—atopic dermatitis	4.29e-05	0.000377	CbGpPWpGaD
Thalidomide—Ill-defined disorder—Prednisone—atopic dermatitis	4.29e-05	0.000255	CcSEcCtD
Thalidomide—Paraesthesia—Triamcinolone—atopic dermatitis	4.28e-05	0.000255	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—CCL22—atopic dermatitis	4.28e-05	0.000376	CbGpPWpGaD
Thalidomide—Feeling abnormal—Prednisolone—atopic dermatitis	4.27e-05	0.000254	CcSEcCtD
Thalidomide—Paraesthesia—Methylprednisolone—atopic dermatitis	4.27e-05	0.000254	CcSEcCtD
Thalidomide—Anaemia—Prednisone—atopic dermatitis	4.27e-05	0.000254	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CD79A—atopic dermatitis	4.26e-05	0.000374	CbGpPWpGaD
Thalidomide—Shock—Dexamethasone—atopic dermatitis	4.26e-05	0.000253	CcSEcCtD
Thalidomide—Shock—Betamethasone—atopic dermatitis	4.26e-05	0.000253	CcSEcCtD
Thalidomide—Dyspnoea—Triamcinolone—atopic dermatitis	4.25e-05	0.000253	CcSEcCtD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—MAPK8—atopic dermatitis	4.25e-05	0.000373	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by Interleukins—IL6—atopic dermatitis	4.25e-05	0.000373	CbGpPWpGaD
Thalidomide—Nervous system disorder—Dexamethasone—atopic dermatitis	4.24e-05	0.000253	CcSEcCtD
Thalidomide—Nervous system disorder—Betamethasone—atopic dermatitis	4.24e-05	0.000253	CcSEcCtD
Thalidomide—Agitation—Prednisone—atopic dermatitis	4.24e-05	0.000253	CcSEcCtD
Thalidomide—Thrombocytopenia—Dexamethasone—atopic dermatitis	4.24e-05	0.000252	CcSEcCtD
Thalidomide—Thrombocytopenia—Betamethasone—atopic dermatitis	4.24e-05	0.000252	CcSEcCtD
Thalidomide—Tachycardia—Dexamethasone—atopic dermatitis	4.22e-05	0.000251	CcSEcCtD
Thalidomide—Tachycardia—Betamethasone—atopic dermatitis	4.22e-05	0.000251	CcSEcCtD
Thalidomide—Angioedema—Prednisone—atopic dermatitis	4.22e-05	0.000251	CcSEcCtD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	4.22e-05	0.00037	CbGpPWpGaD
Thalidomide—Dyspepsia—Triamcinolone—atopic dermatitis	4.2e-05	0.00025	CcSEcCtD
Thalidomide—Dyspepsia—Methylprednisolone—atopic dermatitis	4.19e-05	0.000249	CcSEcCtD
Thalidomide—Hyperhidrosis—Dexamethasone—atopic dermatitis	4.18e-05	0.000249	CcSEcCtD
Thalidomide—Hyperhidrosis—Betamethasone—atopic dermatitis	4.18e-05	0.000249	CcSEcCtD
Thalidomide—Feeling abnormal—Hydrocortisone—atopic dermatitis	4.17e-05	0.000248	CcSEcCtD
Thalidomide—Malaise—Prednisone—atopic dermatitis	4.17e-05	0.000248	CcSEcCtD
Thalidomide—Vertigo—Prednisone—atopic dermatitis	4.15e-05	0.000247	CcSEcCtD
Thalidomide—Gastrointestinal pain—Hydrocortisone—atopic dermatitis	4.14e-05	0.000247	CcSEcCtD
Thalidomide—Syncope—Prednisone—atopic dermatitis	4.14e-05	0.000247	CcSEcCtD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—MAPK8—atopic dermatitis	4.14e-05	0.000364	CbGpPWpGaD
Thalidomide—Anorexia—Dexamethasone—atopic dermatitis	4.13e-05	0.000246	CcSEcCtD
Thalidomide—Anorexia—Betamethasone—atopic dermatitis	4.13e-05	0.000246	CcSEcCtD
Thalidomide—Urticaria—Prednisolone—atopic dermatitis	4.12e-05	0.000245	CcSEcCtD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL1B—atopic dermatitis	4.12e-05	0.000362	CbGpPWpGaD
Thalidomide—Fatigue—Triamcinolone—atopic dermatitis	4.11e-05	0.000245	CcSEcCtD
Thalidomide—Fatigue—Methylprednisolone—atopic dermatitis	4.1e-05	0.000244	CcSEcCtD
Thalidomide—NFKB1—Activated TLR4 signalling—IL6—atopic dermatitis	4.1e-05	0.00036	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	4.09e-05	0.000359	CbGpPWpGaD
Thalidomide—Pain—Triamcinolone—atopic dermatitis	4.08e-05	0.000243	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—CCL22—atopic dermatitis	4.06e-05	0.000357	CbGpPWpGaD
Thalidomide—Loss of consciousness—Prednisone—atopic dermatitis	4.06e-05	0.000242	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CD79A—atopic dermatitis	4.04e-05	0.000355	CbGpPWpGaD
Thalidomide—Hypotension—Betamethasone—atopic dermatitis	4.04e-05	0.000241	CcSEcCtD
Thalidomide—Hypotension—Dexamethasone—atopic dermatitis	4.04e-05	0.000241	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL1B—atopic dermatitis	4.03e-05	0.000354	CbGpPWpGaD
Thalidomide—Urticaria—Hydrocortisone—atopic dermatitis	4.02e-05	0.00024	CcSEcCtD
Thalidomide—NFKB1—Immune System—STAT6—atopic dermatitis	4.01e-05	0.000352	CbGpPWpGaD
Thalidomide—Body temperature increased—Hydrocortisone—atopic dermatitis	4e-05	0.000238	CcSEcCtD
Thalidomide—Abdominal pain—Hydrocortisone—atopic dermatitis	4e-05	0.000238	CcSEcCtD
Thalidomide—Convulsion—Prednisone—atopic dermatitis	4e-05	0.000238	CcSEcCtD
Thalidomide—Hypertension—Prednisone—atopic dermatitis	3.99e-05	0.000237	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Betamethasone—atopic dermatitis	3.94e-05	0.000235	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Dexamethasone—atopic dermatitis	3.94e-05	0.000235	CcSEcCtD
Thalidomide—Myalgia—Prednisone—atopic dermatitis	3.93e-05	0.000234	CcSEcCtD
Thalidomide—Arthralgia—Prednisone—atopic dermatitis	3.93e-05	0.000234	CcSEcCtD
Thalidomide—Feeling abnormal—Triamcinolone—atopic dermatitis	3.93e-05	0.000234	CcSEcCtD
Thalidomide—Feeling abnormal—Methylprednisolone—atopic dermatitis	3.92e-05	0.000233	CcSEcCtD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—TNF—atopic dermatitis	3.92e-05	0.000344	CbGpPWpGaD
Thalidomide—Anxiety—Prednisone—atopic dermatitis	3.92e-05	0.000233	CcSEcCtD
Thalidomide—Insomnia—Dexamethasone—atopic dermatitis	3.91e-05	0.000233	CcSEcCtD
Thalidomide—Insomnia—Betamethasone—atopic dermatitis	3.91e-05	0.000233	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—atopic dermatitis	3.91e-05	0.000232	CcSEcCtD
Thalidomide—NFKB1—Immune System—CARD11—atopic dermatitis	3.9e-05	0.000343	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Methylprednisolone—atopic dermatitis	3.89e-05	0.000232	CcSEcCtD
Thalidomide—Paraesthesia—Dexamethasone—atopic dermatitis	3.89e-05	0.000231	CcSEcCtD
Thalidomide—Paraesthesia—Betamethasone—atopic dermatitis	3.89e-05	0.000231	CcSEcCtD
Thalidomide—Discomfort—Prednisone—atopic dermatitis	3.88e-05	0.000231	CcSEcCtD
Thalidomide—TNF—MAPK Signaling Pathway—IL1B—atopic dermatitis	3.88e-05	0.000341	CbGpPWpGaD
Thalidomide—NFKB1—Toll Like Receptor 4 (TLR4) Cascade—IL6—atopic dermatitis	3.85e-05	0.000338	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—atopic dermatitis	3.83e-05	0.000336	CbGpPWpGaD
Thalidomide—Hypersensitivity—Prednisolone—atopic dermatitis	3.82e-05	0.000227	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—CCL27—atopic dermatitis	3.82e-05	0.000335	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—atopic dermatitis	3.81e-05	0.000335	CbGpPWpGaD
Thalidomide—TNF—Selenium Micronutrient Network—IL6—atopic dermatitis	3.81e-05	0.000335	CbGpPWpGaD
Thalidomide—Dyspepsia—Betamethasone—atopic dermatitis	3.81e-05	0.000227	CcSEcCtD
Thalidomide—Dyspepsia—Dexamethasone—atopic dermatitis	3.81e-05	0.000227	CcSEcCtD
Thalidomide—FGFR2—Immune System—STAT6—atopic dermatitis	3.81e-05	0.000334	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by Insulin receptor—IL6—atopic dermatitis	3.81e-05	0.000334	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—MAPK8—atopic dermatitis	3.8e-05	0.000333	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IFNG—atopic dermatitis	3.79e-05	0.000333	CbGpPWpGaD
Thalidomide—Urticaria—Triamcinolone—atopic dermatitis	3.79e-05	0.000226	CcSEcCtD
Thalidomide—Urticaria—Methylprednisolone—atopic dermatitis	3.78e-05	0.000225	CcSEcCtD
Thalidomide—Body temperature increased—Triamcinolone—atopic dermatitis	3.77e-05	0.000224	CcSEcCtD
Thalidomide—Oedema—Prednisone—atopic dermatitis	3.77e-05	0.000224	CcSEcCtD
Thalidomide—Abdominal pain—Methylprednisolone—atopic dermatitis	3.76e-05	0.000224	CcSEcCtD
Thalidomide—Decreased appetite—Dexamethasone—atopic dermatitis	3.76e-05	0.000224	CcSEcCtD
Thalidomide—Decreased appetite—Betamethasone—atopic dermatitis	3.76e-05	0.000224	CcSEcCtD
Thalidomide—Infection—Prednisone—atopic dermatitis	3.74e-05	0.000223	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Betamethasone—atopic dermatitis	3.74e-05	0.000222	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Dexamethasone—atopic dermatitis	3.74e-05	0.000222	CcSEcCtD
Thalidomide—Hypersensitivity—Hydrocortisone—atopic dermatitis	3.73e-05	0.000222	CcSEcCtD
Thalidomide—Fatigue—Betamethasone—atopic dermatitis	3.73e-05	0.000222	CcSEcCtD
Thalidomide—Fatigue—Dexamethasone—atopic dermatitis	3.73e-05	0.000222	CcSEcCtD
Thalidomide—Shock—Prednisone—atopic dermatitis	3.71e-05	0.000221	CcSEcCtD
Thalidomide—FGFR2—Immune System—CARD11—atopic dermatitis	3.7e-05	0.000325	CbGpPWpGaD
Thalidomide—Pain—Dexamethasone—atopic dermatitis	3.7e-05	0.00022	CcSEcCtD
Thalidomide—Pain—Betamethasone—atopic dermatitis	3.7e-05	0.00022	CcSEcCtD
Thalidomide—NFKB1—Cellular responses to stress—CXCL8—atopic dermatitis	3.7e-05	0.000325	CbGpPWpGaD
Thalidomide—Nervous system disorder—Prednisone—atopic dermatitis	3.7e-05	0.00022	CcSEcCtD
Thalidomide—NFKB1—MAPK Signaling Pathway—TNF—atopic dermatitis	3.7e-05	0.000325	CbGpPWpGaD
Thalidomide—PTGS1—Selenium Micronutrient Network—TNF—atopic dermatitis	3.68e-05	0.000323	CbGpPWpGaD
Thalidomide—Tachycardia—Prednisone—atopic dermatitis	3.68e-05	0.000219	CcSEcCtD
Thalidomide—TNF—TNF alpha Signaling Pathway—IL6—atopic dermatitis	3.68e-05	0.000323	CbGpPWpGaD
Thalidomide—Skin disorder—Prednisone—atopic dermatitis	3.66e-05	0.000218	CcSEcCtD
Thalidomide—Hyperhidrosis—Prednisone—atopic dermatitis	3.64e-05	0.000217	CcSEcCtD
Thalidomide—Asthenia—Hydrocortisone—atopic dermatitis	3.63e-05	0.000216	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—CCL27—atopic dermatitis	3.62e-05	0.000318	CbGpPWpGaD
Thalidomide—Anorexia—Prednisone—atopic dermatitis	3.59e-05	0.000214	CcSEcCtD
Thalidomide—Pruritus—Hydrocortisone—atopic dermatitis	3.58e-05	0.000213	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—IFNG—atopic dermatitis	3.57e-05	0.000314	CbGpPWpGaD
Thalidomide—Feeling abnormal—Dexamethasone—atopic dermatitis	3.57e-05	0.000212	CcSEcCtD
Thalidomide—Feeling abnormal—Betamethasone—atopic dermatitis	3.57e-05	0.000212	CcSEcCtD
Thalidomide—TNF—MAPK Signaling Pathway—MAPK8—atopic dermatitis	3.56e-05	0.000313	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—PPARA—atopic dermatitis	3.55e-05	0.000312	CbGpPWpGaD
Thalidomide—Gastrointestinal pain—Betamethasone—atopic dermatitis	3.54e-05	0.000211	CcSEcCtD
Thalidomide—Gastrointestinal pain—Dexamethasone—atopic dermatitis	3.54e-05	0.000211	CcSEcCtD
Thalidomide—Hypersensitivity—Triamcinolone—atopic dermatitis	3.51e-05	0.000209	CcSEcCtD
Thalidomide—Hypersensitivity—Methylprednisolone—atopic dermatitis	3.51e-05	0.000209	CcSEcCtD
Thalidomide—NFKB1—Regulation of toll-like receptor signaling pathway—IL6—atopic dermatitis	3.47e-05	0.000305	CbGpPWpGaD
Thalidomide—Diarrhoea—Hydrocortisone—atopic dermatitis	3.47e-05	0.000206	CcSEcCtD
Thalidomide—Urticaria—Betamethasone—atopic dermatitis	3.44e-05	0.000205	CcSEcCtD
Thalidomide—Urticaria—Dexamethasone—atopic dermatitis	3.44e-05	0.000205	CcSEcCtD
Thalidomide—NFKB1—Adaptive Immune System—CD8A—atopic dermatitis	3.44e-05	0.000302	CbGpPWpGaD
Thalidomide—Musculoskeletal discomfort—Prednisone—atopic dermatitis	3.43e-05	0.000204	CcSEcCtD
Thalidomide—NFKB1—Toll-Like Receptors Cascades—IL6—atopic dermatitis	3.43e-05	0.000301	CbGpPWpGaD
Thalidomide—Dizziness—Prednisolone—atopic dermatitis	3.43e-05	0.000204	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—CCL17—atopic dermatitis	3.42e-05	0.000301	CbGpPWpGaD
Thalidomide—Asthenia—Triamcinolone—atopic dermatitis	3.42e-05	0.000204	CcSEcCtD
Thalidomide—Body temperature increased—Betamethasone—atopic dermatitis	3.42e-05	0.000204	CcSEcCtD
Thalidomide—Body temperature increased—Dexamethasone—atopic dermatitis	3.42e-05	0.000204	CcSEcCtD
Thalidomide—Abdominal pain—Dexamethasone—atopic dermatitis	3.42e-05	0.000204	CcSEcCtD
Thalidomide—Abdominal pain—Betamethasone—atopic dermatitis	3.42e-05	0.000204	CcSEcCtD
Thalidomide—Asthenia—Methylprednisolone—atopic dermatitis	3.41e-05	0.000203	CcSEcCtD
Thalidomide—Insomnia—Prednisone—atopic dermatitis	3.41e-05	0.000203	CcSEcCtD
Thalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—atopic dermatitis	3.39e-05	0.000298	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL1B—atopic dermatitis	3.38e-05	0.000297	CbGpPWpGaD
Thalidomide—Paraesthesia—Prednisone—atopic dermatitis	3.38e-05	0.000201	CcSEcCtD
Thalidomide—Pruritus—Triamcinolone—atopic dermatitis	3.37e-05	0.000201	CcSEcCtD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL2—atopic dermatitis	3.37e-05	0.000296	CbGpPWpGaD
Thalidomide—Pruritus—Methylprednisolone—atopic dermatitis	3.37e-05	0.0002	CcSEcCtD
Thalidomide—Dizziness—Hydrocortisone—atopic dermatitis	3.35e-05	0.000199	CcSEcCtD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	3.35e-05	0.000294	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	3.34e-05	0.000293	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARA—atopic dermatitis	3.33e-05	0.000293	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—CXCL8—atopic dermatitis	3.32e-05	0.000292	CbGpPWpGaD
Thalidomide—Dyspepsia—Prednisone—atopic dermatitis	3.32e-05	0.000197	CcSEcCtD
Thalidomide—FGFR2—Disease—SLC11A1—atopic dermatitis	3.3e-05	0.00029	CbGpPWpGaD
Thalidomide—Decreased appetite—Prednisone—atopic dermatitis	3.28e-05	0.000195	CcSEcCtD
Thalidomide—Rash—Prednisolone—atopic dermatitis	3.27e-05	0.000195	CcSEcCtD
Thalidomide—Dermatitis—Prednisolone—atopic dermatitis	3.27e-05	0.000194	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—CD8A—atopic dermatitis	3.26e-05	0.000286	CbGpPWpGaD
Thalidomide—Diarrhoea—Methylprednisolone—atopic dermatitis	3.26e-05	0.000194	CcSEcCtD
Thalidomide—FGFR2—Signaling by SCF-KIT—IL6—atopic dermatitis	3.26e-05	0.000286	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—MAPK8—atopic dermatitis	3.25e-05	0.000286	CbGpPWpGaD
Thalidomide—Fatigue—Prednisone—atopic dermatitis	3.25e-05	0.000193	CcSEcCtD
Thalidomide—Headache—Prednisolone—atopic dermatitis	3.25e-05	0.000193	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—CCL17—atopic dermatitis	3.25e-05	0.000285	CbGpPWpGaD
Thalidomide—Constipation—Prednisone—atopic dermatitis	3.22e-05	0.000192	CcSEcCtD
Thalidomide—Vomiting—Hydrocortisone—atopic dermatitis	3.22e-05	0.000192	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	3.21e-05	0.000282	CbGpPWpGaD
Thalidomide—Rash—Hydrocortisone—atopic dermatitis	3.19e-05	0.00019	CcSEcCtD
Thalidomide—Dermatitis—Hydrocortisone—atopic dermatitis	3.19e-05	0.00019	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—IL1B—atopic dermatitis	3.18e-05	0.00028	CbGpPWpGaD
Thalidomide—NFKB1—Myometrial Relaxation and Contraction Pathways—IL6—atopic dermatitis	3.18e-05	0.000279	CbGpPWpGaD
Thalidomide—Headache—Hydrocortisone—atopic dermatitis	3.17e-05	0.000189	CcSEcCtD
Thalidomide—PTGS2—Spinal Cord Injury—IL2—atopic dermatitis	3.17e-05	0.000279	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—atopic dermatitis	3.17e-05	0.000278	CbGpPWpGaD
Thalidomide—NFKB1—SIDS Susceptibility Pathways—IL6—atopic dermatitis	3.16e-05	0.000278	CbGpPWpGaD
Thalidomide—Dizziness—Triamcinolone—atopic dermatitis	3.15e-05	0.000188	CcSEcCtD
Thalidomide—Dizziness—Methylprednisolone—atopic dermatitis	3.15e-05	0.000187	CcSEcCtD
Thalidomide—FGFR2—Downstream signaling of activated FGFR—IL6—atopic dermatitis	3.12e-05	0.000274	CbGpPWpGaD
Thalidomide—Feeling abnormal—Prednisone—atopic dermatitis	3.11e-05	0.000185	CcSEcCtD
Thalidomide—Asthenia—Betamethasone—atopic dermatitis	3.11e-05	0.000185	CcSEcCtD
Thalidomide—Asthenia—Dexamethasone—atopic dermatitis	3.11e-05	0.000185	CcSEcCtD
Thalidomide—Gastrointestinal pain—Prednisone—atopic dermatitis	3.08e-05	0.000183	CcSEcCtD
Thalidomide—Nausea—Prednisolone—atopic dermatitis	3.08e-05	0.000183	CcSEcCtD
Thalidomide—FGFR2—Signaling by ERBB4—IL6—atopic dermatitis	3.07e-05	0.000269	CbGpPWpGaD
Thalidomide—Pruritus—Betamethasone—atopic dermatitis	3.06e-05	0.000182	CcSEcCtD
Thalidomide—Pruritus—Dexamethasone—atopic dermatitis	3.06e-05	0.000182	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—MAPK8—atopic dermatitis	3.05e-05	0.000268	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KIF3A—atopic dermatitis	3.05e-05	0.000268	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	3.05e-05	0.000268	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CASP1—atopic dermatitis	3.04e-05	0.000267	CbGpPWpGaD
Thalidomide—Vomiting—Triamcinolone—atopic dermatitis	3.03e-05	0.000181	CcSEcCtD
Thalidomide—Vomiting—Methylprednisolone—atopic dermatitis	3.03e-05	0.00018	CcSEcCtD
Thalidomide—TNF—Spinal Cord Injury—IL6—atopic dermatitis	3.01e-05	0.000265	CbGpPWpGaD
Thalidomide—Nausea—Hydrocortisone—atopic dermatitis	3.01e-05	0.000179	CcSEcCtD
Thalidomide—Rash—Triamcinolone—atopic dermatitis	3.01e-05	0.000179	CcSEcCtD
Thalidomide—Dermatitis—Triamcinolone—atopic dermatitis	3e-05	0.000179	CcSEcCtD
Thalidomide—Rash—Methylprednisolone—atopic dermatitis	3e-05	0.000179	CcSEcCtD
Thalidomide—Dermatitis—Methylprednisolone—atopic dermatitis	3e-05	0.000178	CcSEcCtD
Thalidomide—Urticaria—Prednisone—atopic dermatitis	2.99e-05	0.000178	CcSEcCtD
Thalidomide—Headache—Triamcinolone—atopic dermatitis	2.99e-05	0.000178	CcSEcCtD
Thalidomide—Headache—Methylprednisolone—atopic dermatitis	2.98e-05	0.000177	CcSEcCtD
Thalidomide—Body temperature increased—Prednisone—atopic dermatitis	2.98e-05	0.000177	CcSEcCtD
Thalidomide—Abdominal pain—Prednisone—atopic dermatitis	2.98e-05	0.000177	CcSEcCtD
Thalidomide—PTGS1—Selenium Micronutrient Network—IL6—atopic dermatitis	2.97e-05	0.000261	CbGpPWpGaD
Thalidomide—Diarrhoea—Dexamethasone—atopic dermatitis	2.96e-05	0.000176	CcSEcCtD
Thalidomide—Diarrhoea—Betamethasone—atopic dermatitis	2.96e-05	0.000176	CcSEcCtD
Thalidomide—FGFR2—Downstream signal transduction—IL6—atopic dermatitis	2.93e-05	0.000257	CbGpPWpGaD
Thalidomide—PTGS2—Selenium Micronutrient Network—TNF—atopic dermatitis	2.92e-05	0.000257	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR—IL6—atopic dermatitis	2.91e-05	0.000256	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by ERBB2—IL6—atopic dermatitis	2.9e-05	0.000255	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—MAPK8—atopic dermatitis	2.9e-05	0.000254	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KIF3A—atopic dermatitis	2.89e-05	0.000254	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CASP1—atopic dermatitis	2.89e-05	0.000253	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 signaling—IL6—atopic dermatitis	2.89e-05	0.000253	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL5—atopic dermatitis	2.88e-05	0.000253	CbGpPWpGaD
Thalidomide—Dizziness—Dexamethasone—atopic dermatitis	2.86e-05	0.00017	CcSEcCtD
Thalidomide—Dizziness—Betamethasone—atopic dermatitis	2.86e-05	0.00017	CcSEcCtD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	2.86e-05	0.000251	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—atopic dermatitis	2.86e-05	0.000251	CbGpPWpGaD
Thalidomide—Nausea—Triamcinolone—atopic dermatitis	2.83e-05	0.000169	CcSEcCtD
Thalidomide—Nausea—Methylprednisolone—atopic dermatitis	2.83e-05	0.000168	CcSEcCtD
Thalidomide—TNF—Adipogenesis—IL6—atopic dermatitis	2.79e-05	0.000245	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—atopic dermatitis	2.78e-05	0.000244	CbGpPWpGaD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—atopic dermatitis	2.78e-05	0.000244	CbGpPWpGaD
Thalidomide—Hypersensitivity—Prednisone—atopic dermatitis	2.78e-05	0.000165	CcSEcCtD
Thalidomide—NFKB1—Innate Immune System—NFKBIA—atopic dermatitis	2.77e-05	0.000244	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL11—atopic dermatitis	2.76e-05	0.000242	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CMA1—atopic dermatitis	2.76e-05	0.000242	CbGpPWpGaD
Thalidomide—Vomiting—Dexamethasone—atopic dermatitis	2.75e-05	0.000164	CcSEcCtD
Thalidomide—Vomiting—Betamethasone—atopic dermatitis	2.75e-05	0.000164	CcSEcCtD
Thalidomide—NFKB1—Immune System—TLR2—atopic dermatitis	2.75e-05	0.000242	CbGpPWpGaD
Thalidomide—NFKB1—Cellular Senescence—IL6—atopic dermatitis	2.75e-05	0.000242	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL5—atopic dermatitis	2.74e-05	0.00024	CbGpPWpGaD
Thalidomide—Rash—Dexamethasone—atopic dermatitis	2.73e-05	0.000162	CcSEcCtD
Thalidomide—Rash—Betamethasone—atopic dermatitis	2.73e-05	0.000162	CcSEcCtD
Thalidomide—Dermatitis—Dexamethasone—atopic dermatitis	2.73e-05	0.000162	CcSEcCtD
Thalidomide—Dermatitis—Betamethasone—atopic dermatitis	2.73e-05	0.000162	CcSEcCtD
Thalidomide—FGFR2—DAP12 interactions—IL6—atopic dermatitis	2.71e-05	0.000238	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—IL6—atopic dermatitis	2.71e-05	0.000238	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—IL6—atopic dermatitis	2.71e-05	0.000238	CbGpPWpGaD
Thalidomide—Headache—Betamethasone—atopic dermatitis	2.71e-05	0.000161	CcSEcCtD
Thalidomide—Headache—Dexamethasone—atopic dermatitis	2.71e-05	0.000161	CcSEcCtD
Thalidomide—TNF—Developmental Biology—PPARA—atopic dermatitis	2.71e-05	0.000238	CbGpPWpGaD
Thalidomide—Asthenia—Prednisone—atopic dermatitis	2.7e-05	0.000161	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR—IL6—atopic dermatitis	2.69e-05	0.000236	CbGpPWpGaD
Thalidomide—Pruritus—Prednisone—atopic dermatitis	2.67e-05	0.000159	CcSEcCtD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—IL6—atopic dermatitis	2.67e-05	0.000234	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NFKBIA—atopic dermatitis	2.66e-05	0.000234	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—IL6—atopic dermatitis	2.65e-05	0.000233	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—atopic dermatitis	2.64e-05	0.000232	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NFKBIA—atopic dermatitis	2.63e-05	0.000231	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL11—atopic dermatitis	2.62e-05	0.00023	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CMA1—atopic dermatitis	2.62e-05	0.00023	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—TLR2—atopic dermatitis	2.61e-05	0.000229	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GLB1—atopic dermatitis	2.61e-05	0.000229	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—STAT6—atopic dermatitis	2.59e-05	0.000228	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD79A—atopic dermatitis	2.59e-05	0.000227	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—GLB1—atopic dermatitis	2.58e-05	0.000227	CbGpPWpGaD
Thalidomide—Diarrhoea—Prednisone—atopic dermatitis	2.58e-05	0.000154	CcSEcCtD
Thalidomide—Nausea—Betamethasone—atopic dermatitis	2.57e-05	0.000153	CcSEcCtD
Thalidomide—Nausea—Dexamethasone—atopic dermatitis	2.57e-05	0.000153	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—NFKBIA—atopic dermatitis	2.53e-05	0.000222	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CASP8—atopic dermatitis	2.5e-05	0.00022	CbGpPWpGaD
Thalidomide—Dizziness—Prednisone—atopic dermatitis	2.49e-05	0.000148	CcSEcCtD
Thalidomide—PTGS1—Metabolism—ADSL—atopic dermatitis	2.48e-05	0.000218	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—STAT6—atopic dermatitis	2.46e-05	0.000216	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD79A—atopic dermatitis	2.45e-05	0.000216	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GLB1—atopic dermatitis	2.45e-05	0.000215	CbGpPWpGaD
Thalidomide—TNF—SIDS Susceptibility Pathways—IL6—atopic dermatitis	2.41e-05	0.000212	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—IL6—atopic dermatitis	2.4e-05	0.000211	CbGpPWpGaD
Thalidomide—Vomiting—Prednisone—atopic dermatitis	2.4e-05	0.000143	CcSEcCtD
Thalidomide—Rash—Prednisone—atopic dermatitis	2.38e-05	0.000141	CcSEcCtD
Thalidomide—FGFR2—Innate Immune System—CASP8—atopic dermatitis	2.37e-05	0.000209	CbGpPWpGaD
Thalidomide—Dermatitis—Prednisone—atopic dermatitis	2.37e-05	0.000141	CcSEcCtD
Thalidomide—Headache—Prednisone—atopic dermatitis	2.36e-05	0.000141	CcSEcCtD
Thalidomide—PTGS2—Selenium Micronutrient Network—IL6—atopic dermatitis	2.36e-05	0.000207	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TNF—atopic dermatitis	2.31e-05	0.000203	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR3—atopic dermatitis	2.25e-05	0.000198	CbGpPWpGaD
Thalidomide—Nausea—Prednisone—atopic dermatitis	2.24e-05	0.000133	CcSEcCtD
Thalidomide—FGFR2—Signaling Pathways—CCR3—atopic dermatitis	2.13e-05	0.000187	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL18—atopic dermatitis	2.12e-05	0.000186	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD8A—atopic dermatitis	2.08e-05	0.000183	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—IL6—atopic dermatitis	2.08e-05	0.000183	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CD4—atopic dermatitis	2.06e-05	0.000181	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GLB1—atopic dermatitis	2.05e-05	0.00018	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL18—atopic dermatitis	2.01e-05	0.000176	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TAC1—atopic dermatitis	2e-05	0.000176	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NPS—atopic dermatitis	2e-05	0.000176	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK8—atopic dermatitis	1.99e-05	0.000174	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—IL6—atopic dermatitis	1.98e-05	0.000174	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—atopic dermatitis	1.98e-05	0.000174	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CD4—atopic dermatitis	1.97e-05	0.000173	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ADSL—atopic dermatitis	1.97e-05	0.000173	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCR3—atopic dermatitis	1.97e-05	0.000173	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CD4—atopic dermatitis	1.95e-05	0.000171	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—IL6—atopic dermatitis	1.95e-05	0.000171	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GLB1—atopic dermatitis	1.93e-05	0.00017	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GLB1—atopic dermatitis	1.93e-05	0.000169	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NPS—atopic dermatitis	1.9e-05	0.000167	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TAC1—atopic dermatitis	1.9e-05	0.000167	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.88e-05	0.000165	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CD4—atopic dermatitis	1.87e-05	0.000164	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCR3—atopic dermatitis	1.87e-05	0.000164	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—IL6—atopic dermatitis	1.86e-05	0.000164	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL5—atopic dermatitis	1.86e-05	0.000164	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ADSL—atopic dermatitis	1.85e-05	0.000163	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—IL6—atopic dermatitis	1.85e-05	0.000162	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ADSL—atopic dermatitis	1.85e-05	0.000162	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GLB1—atopic dermatitis	1.82e-05	0.00016	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL5—atopic dermatitis	1.77e-05	0.000155	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ADSL—atopic dermatitis	1.75e-05	0.000153	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—MAPK8—atopic dermatitis	1.74e-05	0.000153	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CCR5—atopic dermatitis	1.67e-05	0.000147	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—MAPK8—atopic dermatitis	1.65e-05	0.000145	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SLC11A1—atopic dermatitis	1.64e-05	0.000144	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NFKBIA—atopic dermatitis	1.62e-05	0.000142	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL10—atopic dermatitis	1.59e-05	0.00014	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—atopic dermatitis	1.57e-05	0.000138	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TNF—atopic dermatitis	1.56e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NFKBIA—atopic dermatitis	1.53e-05	0.000135	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL10—atopic dermatitis	1.51e-05	0.000132	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.5e-05	0.000131	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GLB1—atopic dermatitis	1.49e-05	0.000131	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CASP8—atopic dermatitis	1.46e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADSL—atopic dermatitis	1.43e-05	0.000125	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CASP8—atopic dermatitis	1.38e-05	0.000121	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL5—atopic dermatitis	1.37e-05	0.00012	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GLB1—atopic dermatitis	1.36e-05	0.000119	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.33e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADSL—atopic dermatitis	1.3e-05	0.000114	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL5—atopic dermatitis	1.3e-05	0.000114	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NGF—atopic dermatitis	1.27e-05	0.000111	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—IL6—atopic dermatitis	1.26e-05	0.000111	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNG—atopic dermatitis	1.24e-05	0.000109	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCR5—atopic dermatitis	1.23e-05	0.000108	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NGF—atopic dermatitis	1.2e-05	0.000106	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CD4—atopic dermatitis	1.2e-05	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IFNG—atopic dermatitis	1.18e-05	0.000103	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCR5—atopic dermatitis	1.17e-05	0.000103	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GLB1—atopic dermatitis	1.16e-05	0.000102	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD4—atopic dermatitis	1.14e-05	9.98e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADSL—atopic dermatitis	1.11e-05	9.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—atopic dermatitis	1.11e-05	9.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—atopic dermatitis	1.11e-05	9.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL2—atopic dermatitis	1.1e-05	9.67e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	1.09e-05	9.54e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—atopic dermatitis	1.05e-05	9.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—atopic dermatitis	1.05e-05	9.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CD4—atopic dermatitis	1.05e-05	9.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL2—atopic dermatitis	1.05e-05	9.18e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NFKBIA—atopic dermatitis	1.04e-05	9.18e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK8—atopic dermatitis	1.01e-05	8.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NFKBIA—atopic dermatitis	9.91e-06	8.71e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	9.9e-06	8.7e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK8—atopic dermatitis	9.62e-06	8.45e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—atopic dermatitis	9.59e-06	8.42e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—atopic dermatitis	8.46e-06	7.43e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARA—atopic dermatitis	8.39e-06	7.37e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCR5—atopic dermatitis	8.29e-06	7.28e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CXCL8—atopic dermatitis	7.45e-06	6.55e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL2—atopic dermatitis	7.12e-06	6.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CXCL8—atopic dermatitis	7.07e-06	6.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL2—atopic dermatitis	6.76e-06	5.94e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARA—atopic dermatitis	6.66e-06	5.85e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK8—atopic dermatitis	6.55e-06	5.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—atopic dermatitis	6.47e-06	5.69e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARA—atopic dermatitis	6.27e-06	5.51e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARA—atopic dermatitis	6.26e-06	5.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK8—atopic dermatitis	6.22e-06	5.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—atopic dermatitis	6.14e-06	5.4e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARA—atopic dermatitis	5.91e-06	5.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—atopic dermatitis	5.67e-06	4.98e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CD4—atopic dermatitis	5.21e-06	4.57e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARA—atopic dermatitis	4.84e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARA—atopic dermatitis	4.41e-06	3.87e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—atopic dermatitis	4.19e-06	3.68e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—atopic dermatitis	3.97e-06	3.49e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARA—atopic dermatitis	3.77e-06	3.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—atopic dermatitis	2.82e-06	2.47e-05	CbGpPWpGaD
